BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2590539)

  • 1. Monoclonal B-cells in blood in non-Hodgkin lymphoma. Correlation with clinical features and prognoses.
    Lindh J; Johansson H; Lenner P; Roos G
    Acta Oncol; 1989; 28(5):641-6. PubMed ID: 2590539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic significance of monoclonal small cells in the peripheral blood and bone marrow of various B-cell lymphomas.
    Nakano M; Kawanishi Y; Kuge S; Kuriyama Y; Kuwabara S; Yaguchi M; Toyama K
    Blood; 1992 Jun; 79(12):3253-60. PubMed ID: 1375848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fraction of S-phase cells in blood mononuclear cells in non-Hodgkin's lymphomas--correlation with clinical features and prognosis.
    Lindh J; Jonsson H; Lenner P; Roos G
    Eur J Haematol; 1989 Apr; 42(4):331-8. PubMed ID: 2785930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
    Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
    Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone.
    Rossini F; Terruzzi E; Perego D; Miccolis I; Rivolta F; Manca E; Pogliani EM
    Cancer; 2004 Jan; 100(2):350-5. PubMed ID: 14716771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radiotherapy of primary extranodal non-Hodgkin's lymphoma of the head and neck region. Results of a prospective multicenter study. Study Group NHL: early studies].
    Hoederath A; Sack H; Stuschke M; Lampka E
    Strahlenther Onkol; 1996 Jul; 172(7):356-66; discussion 367-8. PubMed ID: 8693402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.
    Siegert W; Nerl C; Engelhard M; Brittinger G; Tiemann M; Parwaresch R; Heinz R; Huhn D
    Br J Haematol; 1994 Jul; 87(3):529-34. PubMed ID: 7527646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
    Hagemeister F; Rodriguez MA; Deitcher SR; Younes A; Fayad L; Goy A; Dang NH; Forman A; McLaughlin P; Medeiros LJ; Pro B; Romaguera J; Samaniego F; Silverman JA; Sarris A; Cabanillas F
    Br J Haematol; 2013 Sep; 162(5):631-8. PubMed ID: 23802738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.
    Cabanillas F; Cotto M; Liboy I; Rivera E; Pavia OA; Bruno M
    Leuk Lymphoma; 2012 Oct; 53(10):1929-33. PubMed ID: 22448918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
    Chan H; Jackson S; McLay J; Knox A; Lee J; Wang S; Issa S
    Leuk Lymphoma; 2016 Nov; 57(11):2584-92. PubMed ID: 26943235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
    Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
    J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in chemotherapy for large cell lymphoma.
    Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the response of advanced diffuse large cell lymphomas (LSG classification) to weekly CHOP therapy].
    Shimizu K; Hara K; Kunii A
    Rinsho Ketsueki; 1989 Mar; 30(3):309-15. PubMed ID: 2769954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group.
    Conlan MG; Bast M; Armitage JO; Weisenburger DD
    J Clin Oncol; 1990 Jul; 8(7):1163-72. PubMed ID: 1694234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma glutathione S-Transferase P1-1 as a prognostic factor in patients with advanced non-Hodgkin's lymphoma (stages III and IV).
    Katahira T; Takayama T; Miyanishi K; Hayashi T; Ikeda T; Takahashi Y; Takimoto R; Matsunaga T; Kato J; Niitsu Y
    Clin Cancer Res; 2004 Dec; 10(23):7934-40. PubMed ID: 15585627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A
    Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial chemotherapy with an age-adjusted CHOP-schedule in non-Hodgkin lymphomas with unfavorable prognosis. A study of the I.G.C.I.
    Heinz R; Pawlicki M; Losonczy H; Varbiro M; Benedek S; Konopka L; Krc I; Brugiatelli M
    Haematologica; 1986; 71(6):473-9. PubMed ID: 3104156
    [No Abstract]   [Full Text] [Related]  

  • 18. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
    McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
    Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Hodgkin's lymphomas.
    Theodossiou C; Schwarzenberger P
    Clin Obstet Gynecol; 2002 Sep; 45(3):820-9. PubMed ID: 12370624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.